Good News for Hospitalized COVID Patients

A Monoclonal Antibody (MAB) treatment can help reduce the risk of death in patients hospitalized with COVID-19, reveals a new study published in The Lancet Respiratory Medicine.

The therapy, Tixagevimab/Cilgavimab, was developed and deployed quickly in response to the pandemic. Data were analyzed as part of an international NIH-sponsored clinical trial, including a site at Duke that enrolled about 10% of the study participants.

Repurposed Drug may Not Improve COVID-19 Pneumonia
Tocilizumab, a monoclonal antibody treatment, may not reduce ventilator use and shorten hospital stays for patients with severe COVID-19.

‘Monoclonal antibody treatment plays a major role in the prevention, and treatment of early disease, and saves the lives of hospitalized Covid-19 patients.’

Tweet it Now

“In the very early days of COVID, approximately 25 percent of hospitalized patients died from their illness, and there was a huge imperative to find something that works,” said co-lead author Thomas Holland, M.D., an infectious disease specialist and associate professor of medicine at Duke.

“Now, with better therapies, in addition to better population immunity from vaccination and prior infections, that number is down. We still have work to do, and trials like this one help point us to additional therapies that may benefit our patients.”

Data on another successful approach, using the immune modulator Baricitinib in combination with the antiviral Remdesivir, were also recently reported in The Lancet Respiratory Medicine. Lead author Cameron Wolfe, M.D. is an infectious disease specialist and Associate Professor of Medicine at Duke.

Marburg and Ravn Virus Infection: Monoclonal Antibody Found to Be Effective for Treatment
Marburg and Ravn virus infections can be treated successfully by using monoclonal antibodies for treatment.

“The big picture is, Monoclonal Antibodies are a full-spectrum treatment,” Wolfe said. “They have a role in prevention, treatment of early disease, and hospitalized respiratory failure. We are hopeful this could be another class of medications for use in hospitals for COVID patients.”

Monoclonal Antibody Treatment

In the study of Tixagevimab/Cilgavimab, the phase 3 placebo-controlled trial included 1,455 patients and took place at 81 sites on four continents. Duke enrolled 147 patients, making it the highest enrolling site.

Antibody Treatment Effective Against Hemolytic-uremic Syndrome
Scientists have reported successful treatment of 3 young children with Eculizumab who were suffering from a severe hemolytic-uremic syndrome (HUS) after an infection with E.coli bacteria.

Patients were randomized and infused with Tixagevimab/Cilgavimab or a placebo, in addition to remdesivir and other standard care.

By day 90, sustained recovery was achieved by 87% of people who were given Tixagevimab/Cilgavimab and 84% of placebo group participants. Mortality was lower by nearly 4% in the Tixagevimab/Cilgavimab group.

Convalescent Plasma to Treat Hospitalized COVID-19 Patients
Decline in convalescent plasma use at US hospitals linked to higher COVID-19 mortality rate gives new hope about deciding the use of plasma therapy in COVID-19.

“One out of every three patients who would have died without the treatment survived after receiving the monoclonal antibodies,” said co-lead author Adit Ginde, MD, MPH, Professor of Emergency Medicine at the University of Colorado School of Medicine and Emergency Department Physician at UCHealth University of Colorado Hospital.

“That’s a remarkable signal for the benefit and suggests that this and other similar treatments may save lives in patients with severe COVID-19.”

Source-Newswise